Investment
Features
FeesSafety
Academy
More
Pluang+

Compare UBS Group AG Registered Ordinary Shares (UBS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

UBS Group AG Registered Ordinary SharesTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

UBS Group AG Registered Ordinary Shares vs Zimmer Biomet Holdings Inc — how do they compare? UBS Group AG Registered Ordinary Shares trades at $47.89 (market cap $142.70B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 8.4× Zimmer Biomet Holdings Inc's market cap, and UBS Group AG Registered Ordinary Shares pays the higher dividend (2.34%). Which is the better fit depends on your goals — on Pluang, investors hold UBS Group AG Registered Ordinary Shares for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

UBSZBH
Market Cap
$142.70B$16.95B
Volume
2,096,0902,505,240
Sector
FinancialsHealth
52-Week High
$55.72$103.98
52-Week Low
$36.41$79.58
Typical Hold Time
0 Days89 Days
Enterprise Value
$314.41B$24.02B
Dividend Yield
2.34%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

UBS Group AG Registered Ordinary Shares

No Aura AI signal available yet.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.

The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

UBS
100% Buy0% Sell
Avg holding period · 0 Days
ZBH
100% Buy0% Sell
Avg holding period · 89 Days

Top news

Latest headlines on both assets

About UBS Group AG Registered Ordinary Shares

UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.

Read more on UBS →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →